John Zhong
Council Member
Dr. John Zhong is the Vice President of Biometrics at REGENXBIO, a leading gene
therapy company. Before joining REGENXBIO, he was a Biostatistics Group Head
at Biogen, leading his teams to provide statistical strategy and support for
Early Development, Immunology, and Rare Disease in all phases of clinical
development. He also led the Innovative Analytics group and played a critical
role in the use of innovative statistical methods and trial designs across
multiple assets. Prior to Biogen, John was a Senior Director at Human Genome
Sciences, accountable for statistical strategy and support to all phases of
clinical development in autoimmune disease and infectious disease areas. His
work has brought multiple new treatments to patients with serious unmet needs.
In the industry, John actively promoted statistical innovation in drug
development and brought industry’s voice to regulatory innovation. John served
in FDA’s expert panel for the public meeting on “Promoting the Use of Complex
Innovative Designs in Clinical Trials”. He made a positive impact on the design
of FDA’s Complex Innovative Designs Pilot program. Currently, John is
a Rapporteur at the ICH, leading the E20 Expert Working Group to develop an
international regulatory guideline on Adaptive Clinical Trials. John received
his PhD in Mathematical Statistics from the University of Maryland at College
Park. He has coauthored over 50 manuscripts in peer reviewed medical and
statistical journals and more than 100 presentations.
